Royalty Pharma (RPRX) PT Raised to $51 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Price: $67.56 +1.75%
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 11 | New: 1
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 11 | New: 1
Join SI Premium – FREE
Goldman Sachs analyst Asad Haider raised the price target on Royalty Pharma (NASDAQ: RPRX) to $51.00 (from $45.00) while maintaining a Buy rating.
You May Also Be Interested In
- UBS Downgrades PagSeguro (PAGS) to Neutral
- SmartRent (SMRT) PT Raised to $2.25 at B.Riley
- Deutsche Bank Upgrades Frontier Group Holdings Inc (ULCC) to Buy
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
